• Suptavumab Does Not Meet Primary Endpoint americanpharmaceuticalreview
    August 15, 2017
    Regeneron Pharmaceuticals announced a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of preventing medically-attended RSV infections in infants.
PharmaSources Customer Service